Atrion Reports First Quarter Results
Atrion Corporation (Nasdaq - ATRI) reported revenues of $39.2 million for Q1 2021, down from $43.6 million in Q1 2020. Net income decreased to $7.7 million, with diluted earnings per share at $4.22, compared to $4.79 last year. Sequentially, revenues increased by $7.0 million, indicating recovery from previous declines. The company anticipates continued growth in elective surgeries as COVID-19 restrictions ease, despite modest second-quarter expectations. Gross margins fell from 46% to 42% due to increased employee costs during the pandemic, although operating income remained strong at 23% of sales.
- Sequential revenue growth of $7.0 million compared to Q4 2020.
- Operating income strong at 23% of sales.
- Cash and investments increased slightly to $88.5 million.
- Revenue decline from $43.6 million in Q1 2020 to $39.2 million in Q1 2021.
- Net income decreased from $8.9 million in Q1 2020 to $7.7 million in Q1 2021.
- Gross margins fell from 46% to 42% due to increased costs.
ALLEN, Texas, May 10, 2021 (GLOBE NEWSWIRE) -- Atrion Corporation (Nasdaq - ATRI) today announced that revenues for the quarter ended March 31, 2021 were
Commenting on results for the first quarter of 2021 and the outlook for the remainder of 2021, Mr. Battat stated, “I am very pleased to report strong growth in quarterly sequential sales, with revenues for the first quarter of 2021 increasing by
Addressing comparisons with the first quarter of 2020, Mr. Battat added, “While the effect of COVID-19 on revenues is diminishing, we are continuing to employ enhanced safety measures in our facilities to protect our workforce, even though this impacts our efficiency and skews pre-pandemic comparisons. Moreover, we have addressed the added financial burdens facing our employees due to the pandemic for expenses such as child care and remote schooling by increasing pay for our manufacturing employees. These cost increases, which we incurred in the just-completed first quarter and are continuing, are the primary reason why gross margins declined from
Mr. Battat concluded, “Cash and short and long term investments increased slightly to
Atrion Corporation develops and manufactures products primarily for medical applications. The Company’s website is www.atrioncorp.com.
Statements in this press release that are forward looking are based upon current expectations and actual results or future events may differ materially. Such statements include, but are not limited to, Atrion's expectations regarding a continued increase in elective surgeries in each of the remaining quarters of 2021 and revenues in the second half of 2021 to continue on a growth path. Words such as "expects," "believes," "anticipates," "forecasts," "intends," "should", "plans," "will" and variations of such words and similar expressions are intended to identify such forward-looking statements. Forward-looking statements contained herein involve numerous risks and uncertainties, and there are a number of factors that could cause actual results or future events to differ materially, including, but not limited to, the following: the risk that the COVID-19 pandemic continues to lead to material delays and cancellations of, or reduced demand for, procedures in which our products are utilized; curtailed or delayed capital spending by hospitals and other healthcare providers; disruption to our supply chain; closures of our facilities; delays in training; delays in gathering clinical evidence; diversion of management and other resources to respond to the COVID-19 outbreak; the impact of global and regional economic and credit market conditions on healthcare spending; the risk that the COVID-19 virus continues to disrupt local economies and to cause economies in our key markets to enter prolonged recessions; changing economic, market and business conditions; acts of war or terrorism; the effects of governmental regulation; the impact of competition and new technologies; slower-than-anticipated introduction of new products or implementation of marketing strategies; implementation of new manufacturing processes or implementation of new information systems; our ability to protect our intellectual property; changes in the prices of raw materials; changes in product mix; intellectual property and product liability claims and product recalls; the ability to attract and retain qualified personnel; and the loss of, or any material reduction in sales to, any significant customers. In addition, assumptions relating to budgeting, marketing, product development and other management decisions are subjective in many respects and thus susceptible to interpretations and periodic review which may cause us to alter our marketing, capital expenditures or other budgets, which in turn may affect our results of operations and financial condition. The foregoing list of factors is not exclusive, and other factors are set forth in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release are made as of the date hereof, and we do not undertake any obligation, and disclaim any duty, to supplement, update or revise such statements, whether as a result of subsequent events, changed expectations or otherwise, except as required by applicable law.
| Contact: | Jeffery Strickland |
| Vice President and Chief Financial Officer | |
| (972) 390-9800 |
ATRION CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
(In thousands, except per share data)
(Unaudited)
| Three Months Ended March 31, | ||||||||
| 2021 | 2020 | |||||||
| Revenues | $ | 39,169 | $ | 43,594 | ||||
| Cost of goods sold | 22,830 | 23,726 | ||||||
| Gross profit | 16,339 | 19,868 | ||||||
| Operating expenses | 7,408 | 8,154 | ||||||
| Operating income | 8,931 | 11,714 | ||||||
| Interest and dividend income | 217 | 462 | ||||||
| Other investment income (loss) | 62 | (997 | ) | |||||
| Other income | 66 | -- | ||||||
| Income before income taxes | 9,276 | 11,179 | ||||||
| Income tax provision | (1,550 | ) | (2,281 | ) | ||||
| Net income | 7,726 | 8,898 | ||||||
| Income per basic share | $ | 4.23 | $ | 4.80 | ||||
| Weighted average basic shares outstanding | 1,826 | 1,853 | ||||||
| Income per diluted share | $ | 4.22 | $ | 4.79 | ||||
| Weighted average diluted shares outstanding | 1,832 | 1,859 | ||||||
ATRION CORPORATION
CONSOLIDATED BALANCE SHEETS
(In thousands)
| Mar. 31, | Dec. 31, | ||||
| ASSETS | 2021 | 2020 | |||
| (Unaudited) | |||||
| Current assets: | |||||
| Cash and cash equivalents | $ | 29,427 | $ | 22,450 | |
| Short-term investments | 18,393 | 19,258 | |||
| Total cash and short-term investments | 47,820 | 41,708 | |||
| Accounts receivable | 20,235 | 16,445 | |||
| Inventories | 49,519 | 50,298 | |||
| Prepaid expenses and other | 2,385 | 3,868 | |||
| Total current assets | 119,959 | 112,319 | |||
Long-term investments | 40,672 | 46,207 | |||
Property, plant and equipment, net | 94,891 | 94,935 | |||
| Other assets | 13,321 | 13,429 | |||
| $ | 268,843 | $ | 266,890 | ||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||
| Current liabilities | 10,777 | 13,636 | |||
| Line of credit | -- | -- | |||
| Other non-current liabilities | 13,315 | 12,812 | |||
| Stockholders’ equity | 244,751 | 240,442 | |||
| $ | 268,843 | $ | 266,890 | ||
FAQ
What were Atrion Corporation's revenues for the first quarter of 2021?
How did Atrion's net income change in Q1 2021 compared to Q1 2020?
What is Atrion's outlook for the remainder of 2021?
What was the diluted earnings per share for ATRI in Q1 2021?
How much cash and investments does Atrion Corporation have?
